Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 2
1975 1
1977 5
1978 2
1979 4
1980 6
1981 5
1982 7
1983 3
1984 2
1985 2
1986 6
1987 3
1988 2
1989 7
1990 5
1991 7
1992 15
1993 4
1994 3
1995 9
1996 8
1997 7
1998 4
1999 2
2000 12
2001 5
2002 3
2003 2
2004 5
2005 2
2006 1
2007 1
2008 2
2009 1
2010 2
2011 2
2012 1
2013 3
2014 3
2015 3
2016 4
2017 4
2018 2
2019 2
2020 3
2021 2
2022 3
2023 1
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

184 results

Results by year

Filters applied: . Clear all
Page 1
Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group.
Kamat AM, Sylvester RJ, Böhle A, Palou J, Lamm DL, Brausi M, Soloway M, Persad R, Buckley R, Colombel M, Witjes JA. Kamat AM, et al. Among authors: lamm dl. J Clin Oncol. 2016 Jun 1;34(16):1935-44. doi: 10.1200/JCO.2015.64.4070. Epub 2016 Jan 25. J Clin Oncol. 2016. PMID: 26811532 Free PMC article. Review.
Editorial Comment.
Lamm DL. Lamm DL. J Urol. 2018 Jun;199(6):1451. doi: 10.1016/j.juro.2017.12.076. Epub 2018 Mar 12. J Urol. 2018. PMID: 29545189 No abstract available.
An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results.
Packiam VT, Lamm DL, Barocas DA, Trainer A, Fand B, Davis RL 3rd, Clark W, Kroeger M, Dumbadze I, Chamie K, Kader AK, Curran D, Gutheil J, Kuan A, Yeung AW, Steinberg GD. Packiam VT, et al. Among authors: lamm dl. Urol Oncol. 2018 Oct;36(10):440-447. doi: 10.1016/j.urolonc.2017.07.005. Epub 2017 Jul 26. Urol Oncol. 2018. PMID: 28755959 Clinical Trial.
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.
Steinberg RL, Thomas LJ, Brooks N, Mott SL, Vitale A, Crump T, Rao MY, Daniels MJ, Wang J, Nagaraju S, DeWolf WC, Lamm DL, Kates M, Hyndman ME, Kamat AM, Bivalacqua TJ, Nepple KG, O'Donnell MA. Steinberg RL, et al. Among authors: lamm dl. J Urol. 2020 May;203(5):902-909. doi: 10.1097/JU.0000000000000688. Epub 2019 Dec 10. J Urol. 2020. PMID: 31821066
Innovation in Bladder Cancer Immunotherapy.
Grossman HB, Lamm DL, Kamat AM, Keefe S, Taylor JA 3rd, Ingersoll MA. Grossman HB, et al. Among authors: lamm dl. J Immunother. 2016 Oct;39(8):291-7. doi: 10.1097/CJI.0000000000000130. J Immunother. 2016. PMID: 27428265 Review.
Editorial comment.
Lamm DL. Lamm DL. Urology. 2011 Oct;78(4):854-5. doi: 10.1016/j.urology.2011.05.059. Urology. 2011. PMID: 21982004 No abstract available.
Bacillus Calmette-Guerin immunotherapy.
Lamm DL. Lamm DL. J Urol. 1987 Aug;138(2):391-2. doi: 10.1016/s0022-5347(17)43158-2. J Urol. 1987. PMID: 3599262 No abstract available.
Carcinoma in situ.
Lamm DL. Lamm DL. Urol Clin North Am. 1992 Aug;19(3):499-508. Urol Clin North Am. 1992. PMID: 1636234 Review.
Bladder cancer, 1996.
Lamm DL, Torti FM. Lamm DL, et al. CA Cancer J Clin. 1996 Mar-Apr;46(2):93-112. doi: 10.3322/canjclin.46.2.93. CA Cancer J Clin. 1996. PMID: 8624800 Free article. Review.
Embryogenesis of chordee.
Kaplan GW, Lamm DL. Kaplan GW, et al. Among authors: lamm dl. J Urol. 1975 Nov;114(5):769-72. doi: 10.1016/s0022-5347(17)67140-4. J Urol. 1975. PMID: 1185878
184 results